Brezosiran and the Phase 1b results will be featured as part of Alnylam’s 10th “RNAi Roundtable” series on October 26, 2026, ...

– Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM Diagnosis – – ‘Play by Play’ Uses Sports to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology ...

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

“2026 is off to a strong start for Alnylam with the end of the first quarter marking one year since the U.S. launch of AMVUTTRA for ATTR-CM, and also representing a significant financial milestone ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2025-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview ...

– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 27, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview ...

Feb 15, 2024 Feb 15, 2024 − Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − ...

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available ...

Net product revenues increased 35% during the third quarter 2023, as compared to the prior year, and 33% at CER. The increase is primarily related to growth in our TTR product revenues driven by the ...